2027 ICD-10-CM Diagnosis Code E70.39Other specified albinism
ICD-10-CM Codes›E00–E89›E70-E88›E70
- Billable — Valid for Submission
- CC — Complication or Comorbidity
- Chronic Condition
E70.39 is a billable ICD-10-CM diagnosis code for other specified albinism. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 642. As a secondary diagnosis, it counts as a complication or comorbidity (CC) and moves an inpatient stay to a higher severity level within its MS-DRG family. It does not count, however, when the principal diagnosis is one of 140 closely related codes. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Other specified and unspecified nutritional and metabolic disorders.
E70.39 no longer risk-adjusts for Medicare Advantage: it mapped to HCC 23 under the retired CMS-HCC V24 model through payment year 2025 but maps to no category in the live V28 model. It still risk-adjusts in the PACE (CMS-HCC V22) category 23, ESRD (V21) category 23, ESRD (V24) category 23, and RxHCC Part D (V08) category 43 for payment year 2027.
Code Identity
Code Classification
Medicare Risk Adjustment (HCC)Billing
E70.39 no longer risk-adjusts for Medicare Advantage: it maps to no payment category in the live CMS-HCC V28 model, although it still risk-adjusts in the other CMS models shown below.
Source: CMS Payment Year 2027 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Albinism-deafness syndrome of Tietz
- Dystopia canthorum
- Griscelli syndrome type 1
- Griscelli syndrome type 3
- Hypopigmentation-immunodeficiency disease
- Immunodeficiency associated with multiple organ system abnormalities
- Immunodeficiency with major anomalies
- Phylloid hypomelanosis
- Piebald trait with neurologic defects syndrome
- Piebaldism
- Profound hearing loss
- Profound sensorineural hearing loss
- Waardenburg syndrome
- Waardenburg syndrome type 3
- Ziprkowski-Margolis syndrome
Instructional NotesGuidance
Instructions from the official ICD-10-CM Tabular List that apply to E70.39: its own notes plus those printed at block E70-E88 and Chapter 4. A note printed at a category, block or chapter applies to every code under it.
Applicable To
Conditions this code is used for: synonyms of the title or, for "other specified" codes, the conditions assigned to it. The list is not exhaustive.
- Piebaldism
Excludes1
Not coded here: the excluded code is never reported together with this one, unless the two conditions are unrelated.
Excludes2
Not included here: the excluded condition is not part of this code, but a patient may have both, so both codes may be reported.
- Ehlers-Danlos syndromes (Q79.6-)
Notes
General instructions on how these codes are used.
- All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.
Source: CMS ICD-10-CM Tabular List. How to read instructional notes.
Referenced in Other NotesGuidance
Instructional notes printed at other codes that name E70.39, its category, or a range that includes it.
Excludes1 4
These codes carry an Excludes1 note naming E70.39: they are not reported together with it, unless the two conditions are unrelated.
- E72 Other disorders of amino-acid metabolismaromatic amino-acid metabolism (E70.-) names E70.-, which includes this code
- R79 Other abnormal findings of blood chemistry
- R79.83 Abnormal findings of blood amino-acid level
- Block R80-R82 Abnormal findings on examination of urine, without diagnosis
Index to Diseases and InjuriesGuidance
Alphabetical index entries that point to this code.
Piebaldism E70.39
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Piebaldism
autosomal dominant, congenital disorder characterized by localized hypomelanosis of the skin and hair. the most familiar feature is a white forelock presenting in 80 to 90 percent of the patients. the underlying defect is possibly related to the differentiation and migration of melanoblasts, as well as to defective development of the neural crest (neurocristopathy). piebaldism may be closely related to waardenburg syndrome.
Patient EducationClinical
Skin Pigmentation Disorders
Pigmentation means coloring. Skin pigmentation disorders affect the color of your skin. Your skin gets its color from a pigment called melanin. Special cells in the skin make melanin. When these cells become damaged or unhealthy, it affects melanin production. Some pigmentation disorders affect just patches of skin.
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert E70.39 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About E70.39Overview
What is the ICD-10 code for other specified albinism?
The ICD-10-CM code for other specified albinism is E70.39 (sometimes written as E7039). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
Is E70.39 (Albinism) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report other specified albinism on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
What MS-DRG does E70.39 group to?
When other specified albinism is the principal diagnosis on an inpatient stay, it groups to MS-DRG 642 (inborn and Other Disorders of Metabolism), which carries a relative weight of 1.3226. Higher weights mean higher Medicare reimbursement.
Is E70.39 a CC or MCC?
CMS lists E70.39 as a CC (complication or comorbidity) for FY 2027. Reported as a secondary diagnosis, it moves the inpatient stay to a higher-weighted DRG within its severity family. It does not count when the principal diagnosis is one of the 140 closely related codes in its exclusion list.
Can E70.39 be reported with a code from E34.5?
Not as a rule. The Excludes1 note at block E70-E88, which applies to E70.39, lists "androgen insensitivity syndrome (E34.5-)". An Excludes1 note means the excluded code is never reported together with this one; the only exception is when the two conditions are unrelated to each other (Official Guidelines, Section I.A.12.a).
Does E70.39 risk-adjust for Medicare Advantage payment?
Not for Medicare Advantage. E70.39 mapped to HCC 23 in the retired CMS-HCC V24 model, which last determined payment in 2025, but it maps to no category in the live V28 model; see all codes that no longer risk-adjust. It still risk-adjusts in the PACE (CMS-HCC V22) category 23 (Other Significant Endocrine and Metabolic Disorders), ESRD (V21) category 23 (Other Significant Endocrine and Metabolic Disorders), ESRD (V24) category 23 (Other Significant Endocrine and Metabolic Disorders), and RxHCC Part D (V08) category 43 (Pituitary, Adrenal Gland, and Other Endocrine and Metabolic Disorders).
